JP2011501656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501656A5 JP2011501656A5 JP2010527128A JP2010527128A JP2011501656A5 JP 2011501656 A5 JP2011501656 A5 JP 2011501656A5 JP 2010527128 A JP2010527128 A JP 2010527128A JP 2010527128 A JP2010527128 A JP 2010527128A JP 2011501656 A5 JP2011501656 A5 JP 2011501656A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- seq
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000008728 vascular permeability Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102220499814 Carbonic anhydrase 2_N62A_mutation Human genes 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102220536901 PRKC apoptosis WT1 regulator protein_L69I_mutation Human genes 0.000 claims 1
- 102220480127 Protein-tyrosine sulfotransferase 1_N60A_mutation Human genes 0.000 claims 1
- 102220494895 Stromal cell-derived factor 2-like protein 1_T46L_mutation Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 102200094891 rs121913566 Human genes 0.000 claims 1
- 102200074783 rs144422014 Human genes 0.000 claims 1
- 102220008795 rs193922245 Human genes 0.000 claims 1
- 102200096229 rs387906796 Human genes 0.000 claims 1
- 102220040412 rs587778307 Human genes 0.000 claims 1
- 102200124875 rs59151893 Human genes 0.000 claims 1
- 102200153731 rs7122277 Human genes 0.000 claims 1
- 102220061206 rs786203134 Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97547107P | 2007-09-26 | 2007-09-26 | |
| PCT/US2008/077622 WO2009042746A1 (en) | 2007-09-26 | 2008-09-25 | Novel antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501656A JP2011501656A (ja) | 2011-01-13 |
| JP2011501656A5 true JP2011501656A5 (enExample) | 2011-11-10 |
Family
ID=40329277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527128A Pending JP2011501656A (ja) | 2007-09-26 | 2008-09-25 | 新規抗体 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7973138B2 (enExample) |
| EP (1) | EP2200700B1 (enExample) |
| JP (1) | JP2011501656A (enExample) |
| KR (1) | KR20100065162A (enExample) |
| CN (1) | CN101888878B (enExample) |
| AR (1) | AR066170A1 (enExample) |
| AU (1) | AU2008304452B2 (enExample) |
| BR (1) | BRPI0816049A2 (enExample) |
| CA (1) | CA2698609A1 (enExample) |
| CL (1) | CL2008002856A1 (enExample) |
| CO (1) | CO6260094A2 (enExample) |
| DK (1) | DK2200700T3 (enExample) |
| HR (1) | HRP20160308T1 (enExample) |
| HU (1) | HUE027911T2 (enExample) |
| MX (1) | MX2010003325A (enExample) |
| MY (1) | MY151191A (enExample) |
| NZ (1) | NZ584838A (enExample) |
| PE (1) | PE20091029A1 (enExample) |
| RU (1) | RU2490277C2 (enExample) |
| SI (1) | SI2200700T1 (enExample) |
| TW (1) | TWI547503B (enExample) |
| WO (1) | WO2009042746A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY151191A (en) | 2007-09-26 | 2014-04-30 | Genentech Inc | Novel antibodies |
| JP6051048B2 (ja) | 2009-03-25 | 2016-12-21 | ジェネンテック， インコーポレイテッド | 新規な抗α５β１抗体及びその使用 |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| CN102875677A (zh) * | 2009-05-08 | 2013-01-16 | 霍夫曼-拉罗奇有限公司 | 人源化抗egfl7抗体及其使用方法 |
| US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
| US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| WO2013152011A1 (en) * | 2012-04-02 | 2013-10-10 | Ab Biosciences, Inc. | Novel human control antibodies and uses therefor |
| ES2749200T3 (es) | 2012-05-10 | 2020-03-19 | Bioatla Llc | Anticuerpos monoclonales multiespecíficos |
| JP6324970B2 (ja) | 2012-09-27 | 2018-05-23 | バイオケア メディカル， エルエルシー | 抗ウロプラキンｉｉ抗体システムおよび方法 |
| WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| CA2896331C (en) * | 2012-12-26 | 2023-08-01 | Oncosynergy, Inc. | Anti-integrin .beta.1 antibody compositions and methods of use thereof |
| CA2898239A1 (en) | 2013-01-23 | 2014-07-31 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
| CN104968682A (zh) * | 2013-02-05 | 2015-10-07 | 英格玛布股份公司 | 针对CD3ε和BCMA的双特异性抗体 |
| EP2962113B1 (en) | 2013-02-28 | 2019-04-03 | Biocare Medical, LLC | Anti-p40 antibodies systems and methods |
| WO2015051320A2 (en) | 2013-10-03 | 2015-04-09 | Biocare Medical, Llc | Anti-sox10 antibody systems and methods |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| JP2021514656A (ja) | 2018-03-02 | 2021-06-17 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート |
| CN108693004B (zh) * | 2018-05-24 | 2020-08-04 | 中国农业科学院农业质量标准与检测技术研究所 | 一种检测菜籽粕中是否掺杂抗生素滤渣的方法 |
| JP7539701B2 (ja) | 2018-06-14 | 2024-08-26 | バイオアトラ インコーポレイテッド | 多重特異性抗体構造体 |
| WO2020205849A1 (en) * | 2019-04-01 | 2020-10-08 | Lakepharma, Inc. | Btla-binding (cd272) antibodies for modulating immune response and treating disease |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114688461B (zh) * | 2020-12-31 | 2025-02-28 | 青岛海尔施特劳斯水设备有限公司 | 一种漏水检测方法及系统 |
| CN113133431A (zh) * | 2021-02-25 | 2021-07-20 | 中南大学 | 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用 |
| CN114073996B (zh) * | 2021-11-24 | 2023-04-14 | 中山大学 | 一种嵌套式微井阵列芯片及其制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540933A (en) | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
| EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
| US20020146410A1 (en) | 1992-05-22 | 2002-10-10 | Helmut Eckert | Monoclonal antibodies and their use |
| US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| DE69531187T2 (de) | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
| KR20010034327A (ko) | 1998-01-23 | 2001-04-25 | 플레믹 크리스티안 | 모노클로날 항체 항 αν-인테그린, 및 피브로넥틴에 대한ανβ6-인테그린 부착을 억제하기 위한 그의 용도 |
| EP1075277B2 (en) | 1998-05-08 | 2012-10-31 | The Regents of the University of California | Methods for detecting and inhibiting angiogenesis |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB9909392D0 (en) | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
| US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| JP2003517816A (ja) | 1999-08-11 | 2003-06-03 | イオス バイオテクノロジー， インコーポレイテッド | 新脈管形成の診断の新規方法、新脈管形成調節因子についてのスクリーニングの組成物および方法 |
| US20020015970A1 (en) | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
| US20020019330A1 (en) | 1999-08-11 | 2002-02-14 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
| US20040009494A1 (en) | 1999-08-11 | 2004-01-15 | Richard Murray | Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators |
| US20040259152A1 (en) | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
| EP1418943A1 (en) | 2001-02-14 | 2004-05-19 | Protein Design Labs, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| EP1463928A2 (en) | 2001-04-18 | 2004-10-06 | Protein Design Labs | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| WO2002098358A2 (en) | 2001-06-04 | 2002-12-12 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
| US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| AU2002347428A1 (en) | 2001-06-18 | 2003-01-02 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20070042360A1 (en) | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20060241067A1 (en) | 2002-06-25 | 2006-10-26 | Varner Judith A | Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| US7749962B2 (en) | 2002-07-16 | 2010-07-06 | University Of Medicine & Dentistry Of Nj | Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| WO2004048938A2 (en) | 2002-11-26 | 2004-06-10 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| WO2004056308A2 (en) | 2002-11-26 | 2004-07-08 | Protein Design Labs, Inc. | CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS |
| EP1625165A2 (en) | 2003-04-03 | 2006-02-15 | Protein Design Labs, Inc. | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
| EP1755659B1 (en) * | 2004-03-24 | 2011-11-02 | Abbott Biotherapeutics Corp. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| HUE025449T2 (en) | 2004-12-09 | 2016-04-28 | Janssen Biotech Inc | Immunoconjugates against Integrin, a method for their preparation and use |
| WO2007060408A2 (en) | 2005-11-23 | 2007-05-31 | Astrazeneca Ab | L-phenylalanine derivatives and their use as integrin antagonists |
| CN101360736A (zh) | 2005-11-23 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | L-丙氨酸衍生物 |
| CN101379028A (zh) | 2006-02-09 | 2009-03-04 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| DK1989231T3 (en) * | 2006-03-21 | 2015-08-24 | Genentech Inc | COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists |
| KR20090027218A (ko) | 2006-05-24 | 2009-03-16 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 면역원성이 감소된, 고친화도 인간 및 인간화된 항-α5β1 인테그린 작용 블로킹 항체 |
| MY151191A (en) | 2007-09-26 | 2014-04-30 | Genentech Inc | Novel antibodies |
| CN101970006B (zh) | 2008-02-05 | 2014-08-06 | 百时美施贵宝公司 | α5-β1抗体和它们的用途 |
-
2008
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 HR HRP20160308TT patent/HRP20160308T1/hr unknown
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en not_active Ceased
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko not_active Abandoned
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
-
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
-
2011
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501656A5 (enExample) | ||
| CN110627906B (zh) | 抗pd-l1/4-1bb双特异性抗体及其用途 | |
| US9758586B2 (en) | Chimeric rabbit/human ROR1 antibodies | |
| DK2493503T3 (en) | DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody | |
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| CN100410275C (zh) | 新的抗igf-ir抗体及其应用 | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| JP2009536921A5 (enExample) | ||
| JP2012521218A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| EP3008093A1 (en) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer | |
| RU2013108054A (ru) | Антитела против а2 тенасцина с и способы их применения | |
| WO2019137397A1 (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| US10519246B2 (en) | Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis | |
| TWI879889B (zh) | 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途 | |
| CN107614530A (zh) | 用于多发性骨髓瘤（mm）的治疗 | |
| WO2021047386A1 (zh) | 靶向caix抗原的纳米抗体及其应用 | |
| CN109265547A (zh) | 一种抗cd47抗体及其应用 | |
| JP2024054123A (ja) | 癌の治療のための配合剤 | |
| CN106164094A (zh) | 双特异性抗原结合多肽 | |
| CN111825766B (zh) | 抗il-4r单域抗体及其应用 | |
| WO2023143535A1 (zh) | 一种靶向il-18bp的抗体及其应用 | |
| US20250109206A1 (en) | Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof | |
| RU2761638C1 (ru) | Антитела против лиганда программируемой смерти (pd-l1) и их применение | |
| EP4435006A1 (en) | Bispecific antibody and use thereof |